Melanotan II: The Complete Guide (2026)

What Is Melanotan II?

Melanotan II (MT-II or MT-2) is a synthetic cyclic peptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It was originally developed at the University of Arizona in the 1990s as a potential preventive agent against skin cancer by stimulating the body's natural tanning response without requiring ultraviolet (UV) radiation exposure.

As a melanocortin peptide, Melanotan II binds to multiple melanocortin receptors (MC1R through MC5R), which gives it a broader range of effects compared to its more selective cousin, Melanotan I (afamelanotide). This non-selective receptor binding profile is responsible for both its observed effects and its wider side effect profile.

Melanotan II is classified as a research peptide and is not approved by the FDA or any major regulatory body for human use. It has been the subject of regulatory warnings from health agencies in multiple countries. Researchers and individuals considering this compound should exercise extra caution and thoroughly understand the associated risks before proceeding.

How Does Melanotan II Work?

Melanotan II exerts its effects primarily through activation of melanocortin receptors. Its mechanism of action involves several interconnected pathways:

MC1R Activation & Melanogenesis

The primary mechanism behind Melanotan II's tanning effects is activation of the melanocortin 1 receptor (MC1R) located on melanocytes — the pigment-producing cells in the skin. When MC1R is stimulated, it triggers a signaling cascade that upregulates the production of eumelanin, the dark pigment responsible for skin tanning. This process, known as melanogenesis, occurs independently of UV exposure, though some minimal UV exposure may enhance the response.

MC3R & MC4R Activation

Unlike the more selective Melanotan I, MT-II also activates MC3R and MC4R receptors. These receptors are found primarily in the brain and are involved in regulating sexual function, appetite, and energy homeostasis. Activation of MC4R in particular is associated with the compound's reported effects on libido and erectile function, as well as its appetite-suppressing properties.

Broad Melanocortin Signaling

Because Melanotan II is a non-selective melanocortin agonist, it activates a wider array of receptors than intended for any single effect. This broad activation profile is what produces its multiple observed effects — tanning, sexual function changes, and appetite modulation — but it also contributes to a more complex side effect profile that users must carefully consider.

Potential Benefits

The following potential benefits are based on published preclinical and limited clinical research. Melanotan II is not approved for any medical use, and these should not be interpreted as guaranteed outcomes. The risks associated with this compound are significant and should be weighed carefully against any perceived benefits.

Skin Tanning Without UV Exposure

The most widely discussed effect of Melanotan II is its ability to stimulate melanin production and darken skin pigmentation without extensive UV exposure. Research suggests that MT-II can induce a significant tanning response, which was the original goal of its development — to potentially reduce UV-related skin damage and skin cancer risk. However, it is critical to note that this intended protective benefit has not been validated through clinical trials, and the compound itself carries its own set of risks.

Libido & Sexual Function Research

Through its activation of MC3R and MC4R receptors in the brain, Melanotan II has been observed to influence sexual arousal and erectile function in both men and women in limited clinical studies. This led to the development of bremelanotide (PT-141), an FDA-approved derivative specifically designed for hypoactive sexual desire disorder. It is important to note that Melanotan II itself is not the same as bremelanotide and is not approved for treating sexual dysfunction.

Appetite Modulation Research

MC4R activation is known to play a role in appetite regulation and energy balance. Some research has observed appetite-suppressing effects associated with Melanotan II use, though this has not been the primary focus of study. The appetite effects are generally considered a secondary observation rather than a validated therapeutic application.

Dosage Guidelines

Disclaimer: The following information is based on protocols described in published research literature and community reports. This is not medical advice. Melanotan II carries significant risks, and you should consult a healthcare professional before considering any research compound. Proceed with extreme caution.

Loading Phase

Community protocols typically describe a loading phase designed to gradually build up melanin production. This commonly involves starting with a very low dose and slowly increasing:

• Starting dose: 0.1mg – 0.25mg per day to assess tolerance
• Gradual increase: Dosage is typically increased over several days to a common loading dose of 0.5mg – 1mg per day
• Loading duration: The loading phase is commonly described as lasting 2–4 weeks, until a desired level of pigmentation is achieved

Maintenance Phase

Once the desired tan has been achieved, community protocols describe reducing frequency to maintain pigmentation:

• Maintenance dose: 0.5mg administered 1–2 times per week
• Some protocols suggest even less frequent dosing, depending on individual response and UV exposure habits

Administration

Melanotan II is most commonly administered via subcutaneous injection, typically in the abdomen. Some community members report timing their doses in the evening due to the nausea side effect, as sleeping through the initial discomfort is a common strategy. Minimal UV exposure (10–20 minutes) is often discussed as a way to enhance the tanning response, though this introduces its own risks.

How to Reconstitute & Administer Melanotan II

Melanotan II typically ships as a lyophilized (freeze-dried) powder in a sealed vial, commonly in 10mg quantities. Reconstitution is the process of adding a sterile solvent to prepare it for use.

What You Need

• Melanotan II lyophilized vial (commonly 10mg)
• Bacteriostatic water (BAC water)
• Insulin syringes (1ml / 100 unit)
• Alcohol swabs

Step-by-Step Reconstitution

1. Clean the vial tops: Wipe the rubber stoppers of both the Melanotan II vial and the bacteriostatic water vial with alcohol swabs.
2. Draw the BAC water: Using an insulin syringe, draw your desired amount of bacteriostatic water. For a 10mg vial, 2ml of BAC water is a common choice, which yields 0.5mg per 0.1ml (10 units on the syringe).
3. Add water slowly: Insert the needle into the Melanotan II vial and let the water drip down the side of the glass. Do not spray directly onto the powder, as this can damage the peptide.
4. Gently swirl: Once the water is added, gently swirl the vial until the powder is fully dissolved. Do not shake vigorously.
5. Store properly: Reconstituted Melanotan II should be stored in the refrigerator (2–8°C). Most sources recommend using it within 4–6 weeks after reconstitution.

Dosage Math Example

If you reconstitute a 10mg vial with 2ml of BAC water:

• 10mg / 2ml = 5mg per ml = 5,000mcg per ml
• 0.25mg (250mcg) dose = 0.05ml = 5 units on an insulin syringe
• 0.5mg (500mcg) dose = 0.1ml = 10 units on an insulin syringe
• 1mg dose = 0.2ml = 20 units on an insulin syringe
• One 10mg vial at 0.5mg/day = 20 days of loading use

Administration Tips

• Subcutaneous injection into abdominal fat is the most commonly described method
• Rotate injection sites to avoid irritation
• Many users report injecting in the evening to sleep through any nausea
• Pinch a fold of skin and insert the needle at a 45-degree angle

Side Effects & Safety

Melanotan II carries a higher risk profile than many other research peptides. Multiple health agencies, including the FDA and the European Medicines Agency (EMA), have issued warnings about this compound. It is essential to understand these risks before considering its use.

Common Side Effects

The following side effects are frequently reported in both research and community contexts:

• Nausea: One of the most commonly reported side effects, particularly at higher doses or during the initial loading phase. Often described as moderate to significant.
• Facial flushing: Reddening of the face shortly after administration is very common and typically temporary.
• Fatigue and drowsiness: Many users report feeling tired after injection, which is one reason evening dosing is common.
• Injection site reactions: Redness, swelling, or mild pain at the injection site.
• Appetite suppression: Reduced hunger is commonly reported due to MC4R activation.

Serious Safety Concerns

Beyond the common side effects, Melanotan II is associated with several serious safety concerns that require careful attention:

Mole Changes & Skin Safety

This is the most critical safety concern with Melanotan II. Because MT-II stimulates melanocyte activity, it can cause significant changes to existing moles, freckles, and nevi. There have been case reports in the medical literature of:

• Existing moles becoming darker, larger, or changing shape
• New moles or nevi appearing
• Atypical mole development that may complicate skin cancer screening
• Concerns about potential masking of melanoma development

Anyone using Melanotan II should have a full-body mole check performed by a dermatologist before starting, during use, and after discontinuation. Any mole that changes in size, shape, color, or border should be evaluated by a dermatologist immediately. Do not ignore changes in your skin.

FDA & Regulatory Warnings

The FDA has issued warnings about Melanotan II products sold online, citing concerns about safety and the lack of approval for human use. Several other national health agencies, including those in Australia, the UK, and Norway, have issued similar warnings. These agencies have noted that products sold online may be contaminated, improperly manufactured, or mislabeled.

Other Serious Risks

• Cardiovascular effects: Some reports describe elevated blood pressure and heart rate. Individuals with cardiovascular conditions should avoid this compound.
• Priapism risk: Prolonged, unwanted erections have been reported, which constitutes a medical emergency if lasting more than 4 hours.
• Hormonal interactions: As a melanocortin agonist, MT-II may interact with various hormonal pathways. The long-term consequences of this are not well understood.
• Unknown long-term effects: There is no long-term safety data for Melanotan II in humans. The effects of chronic use on melanocyte function, skin health, and other organ systems remain unknown.

Who Should Not Use Melanotan II

• Individuals with a personal or family history of melanoma or skin cancer
• Those with a large number of moles or atypical moles
• Pregnant or breastfeeding women
• Individuals with cardiovascular conditions
• Anyone taking medications that affect blood pressure or sexual function
• Individuals under 18 years of age

Where to Buy Melanotan II

If you have carefully weighed the risks and decided to proceed with research, sourcing high-quality Melanotan II is essential. The unregulated nature of this market means product quality varies dramatically. Purchasing from an unreliable source significantly increases the risk of receiving contaminated, underdosed, or mislabeled product. Here are our top recommended vendors for 2026, evaluated on purity, third-party testing, pricing, and customer service.

Disclosure: This page contains affiliate links. If you purchase through our links, we may earn a commission at no extra cost to you. This helps support our independent research and content. We only recommend vendors we have vetted and trust.

Frequently Asked Questions